Event | Placebo | Ramosetron 5 μg |
---|---|---|
(n = 51) | (n = 47) | |
All adverse events | 20 (39.2%) | 27 (57.4%) |
Gastrointestinal disorders | 8 (15.7%) | 13 (27.7%) |
Abdominal discomfort | 0 (0.0%) | 2 (4.3%) |
Constipation | 2 (3.9%) | 0 (0.0%) |
Hard stool | 3 (5.9%) | 9 (19.1%) |
Nausea | 2 (3.9%) | 0 (0.0%) |
Infections and infestations | 4 (7.8%) | 5 (10.6%) |
Nasopharyngitis | 4 (7.8%) | 3 (6.4%) |
Gastroenteritis | 0 (0.0%) | 2 (4.3%) |
Hepatobiliary disorders | 2 (3.9%) | 2 (4.3%) |
Hepatic function abnormal | 2 (3.9%) | 1 (2.1%) |
Skin and subcutaneous tissue disorder | 2 (3.9%) | 3 (6.4%) |
Dermatitis contact | 1 (2.0%) | 2 (4.3%) |